Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors.

ABSTRACT: Regardless of line of therapy, treatment goals in chronic phase chronic myeloid leukemia (CML) are: avoid progression to accelerated phase or blast crisis CML such that patients achieve a life expectancy comparable with that of the general population; avoid adverse events (AEs); and restore and maintain quality of life. The most important prognostic factor for achieving these goals is response to tyrosine kinase inhibitors (TKIs) at key milestones. For patients failing a TKI, a treatment change is mandatory to limit the risk of progression and death. There is currently no precise guideline for patients that fail a second-generation TKI, and there is a paucity of data to guide clinical decision making in this setting. There is, therefore, an unmet need for practical and actionable guidance

SUBMITTER: Hochhaus A 

PROVIDER: S-EPMC7266739 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature